These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35436670)

  • 21. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
    Singh-Franco D; Robles G; Gazze D
    Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of pramlintide for weight loss.
    Dunican KC; Adams NM; Desilets AR
    Ann Pharmacother; 2010 Mar; 44(3):538-45. PubMed ID: 20164472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.
    Kong MF; Stubbs TA; King P; Macdonald IA; Lambourne JE; Blackshaw PE; Perkins AC; Tattersall RB
    Diabetologia; 1998 May; 41(5):577-83. PubMed ID: 9628276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control.
    Weyer C; Maggs DG; Young AA; Kolterman OG
    Curr Pharm Des; 2001 Sep; 7(14):1353-73. PubMed ID: 11472273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile.
    Larsen AT; Gydesen S; Sonne N; Karsdal MA; Henriksen K
    BMC Endocr Disord; 2021 Jan; 21(1):10. PubMed ID: 33413317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.
    Aronne LJ; Halseth AE; Burns CM; Miller S; Shen LZ
    Obesity (Silver Spring); 2010 Sep; 18(9):1739-46. PubMed ID: 20094043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions of amylinergic and melanocortinergic systems in the control of food intake and body weight in rodents.
    Roth JD; D'Souza L; Griffin PS; Athanacio J; Trevaskis JL; Nazarbaghi R; Jodka C; Athanacio J; Hoyt J; Forood B; Parkes DG
    Diabetes Obes Metab; 2012 Jul; 14(7):608-15. PubMed ID: 22276636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose Frequency Optimization of the Dual Amylin and Calcitonin Receptor Agonist KBP-088: Long-Lasting Improvement in Food Preference and Body Weight Loss.
    Larsen AT; Sonne N; Andreassen KV; Karsdal MA; Henriksen K
    J Pharmacol Exp Ther; 2020 May; 373(2):269-278. PubMed ID: 32071103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pramlintide and the treatment of diabetes: a review of the data since its introduction.
    Younk LM; Mikeladze M; Davis SN
    Expert Opin Pharmacother; 2011 Jun; 12(9):1439-51. PubMed ID: 21564002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rodent models of leptin receptor deficiency are less sensitive to amylin.
    Duffy S; Lutz TA; Boyle CN
    Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R856-R865. PubMed ID: 30133304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.
    Gingell JJ; Burns ER; Hay DL
    Endocrinology; 2014 Jan; 155(1):21-6. PubMed ID: 24169554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus.
    Nyholm B; Brock B; Ørskov L; Schmitz O
    Expert Opin Investig Drugs; 2001 Sep; 10(9):1641-52. PubMed ID: 11772274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pramlintide Antagonizes Beta Amyloid (Aβ)- and Human Amylin-Induced Depression of Hippocampal Long-Term Potentiation.
    Kimura R; MacTavish D; Yang J; Westaway D; Jhamandas JH
    Mol Neurobiol; 2017 Jan; 54(1):748-754. PubMed ID: 26768593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development.
    Bower RL; Hay DL
    Br J Pharmacol; 2016 Jun; 173(12):1883-98. PubMed ID: 27061187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-acting amylin analogues for the management of obesity.
    Mathiesen DS; Bagger JI; Knop FK
    Curr Opin Endocrinol Diabetes Obes; 2022 Apr; 29(2):183-190. PubMed ID: 35066542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amylin Acts in the Lateral Dorsal Tegmental Nucleus to Regulate Energy Balance Through Gamma-Aminobutyric Acid Signaling.
    Reiner DJ; Mietlicki-Baase EG; Olivos DR; McGrath LE; Zimmer DJ; Koch-Laskowski K; Krawczyk J; Turner CA; Noble EE; Hahn JD; Schmidt HD; Kanoski SE; Hayes MR
    Biol Psychiatry; 2017 Dec; 82(11):828-838. PubMed ID: 28237459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
    Fineman M; Weyer C; Maggs DG; Strobel S; Kolterman OG
    Horm Metab Res; 2002 Sep; 34(9):504-8. PubMed ID: 12384827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of Amylin in Type 1 and Type 2 Diabetes.
    Hieronymus L; Griffin S
    Diabetes Educ; 2015 Dec; 41(1 Suppl):47S-56S. PubMed ID: 26424675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes.
    Fang J; Landersdorfer CB; Cirincione B; Jusko WJ
    AAPS J; 2013 Jan; 15(1):15-29. PubMed ID: 23054970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
    Fineman MS; Koda JE; Shen LZ; Strobel SA; Maggs DG; Weyer C; Kolterman OG
    Metabolism; 2002 May; 51(5):636-41. PubMed ID: 11979398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.